SPPI:Spectrum Pharmaceuticals Announces ZEVALIN® and Belinostat Abstracts to Be Presented at the American Society of Clinical Oncology Annual Meeting
PPS:$8.50
HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS:SPPI - News), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan) and Belinostat abstracts will be presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held June 3-7, 2011 at the McCormick Place Convention Center in Chicago, Illinois.